X0306 4 2020-06-12 0 0001636050 Axovant Gene Therapies Ltd. AXGT 0001745995 Corcoran Gavin C/O AXOVANT GENE THERAPIES LTD. 11 TIMES SQUARE, 33RD FLOOR NEW YORK NY 10036 0 1 0 0 Chief R&D Officer Common Shares 2020-06-12 4 A 0 16002 0.00 A 16002 D Common Shares 2020-06-12 4 F 0 6211 3.46 D 9791 D Restricted Stock Units 2020-06-12 4 D 0 16002 0.00 D Common Shares 16002 16001 D The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. /s/ Alison Haggerty, Attorney-In-Fact 2020-06-15